Shukra Pharmaceuticals — 360° view

Shukra Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹44 crore and net profit of ₹16 crore for the September 2026 quarter.

Shukra Pharmaceuticals (NSE: SHUKRAPHAR) closed at ₹84.20 on 20 Nov 2026. Its market capitalisation is ₹3,726 crore and it trades at 84.1 times earnings.

Share price
₹84.20 (20 Nov 2026)
Market cap
₹3,726 Cr (20 Nov 2026)
P/E
84.09 (20 Nov 2026)
Revenue
₹44 Cr (September 2026 quarter)
Net profit
₹16 Cr (September 2026 quarter)
ROCE
37.0% (FY26)
ROE
28.9% (FY26)
Book value
₹2.81 (FY26)
Dividend yield
0.01% (last 12 months to 20 Nov 2026)
52-week high / low
₹84.80 / ₹41.40 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SHUKRAPHAR

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.